Although the campaign against HIV has been intensive, it has been focused mainly on the public health implications. Little or no attention is specifically directed at encouraging the public to know their HIV serostatus. The actual public health burden due to this infection is therefore not known. Accurate data on the health burden is critical for national planning on preventive and other interventional measures. Using a semi-structured self-administered questionnaire, we interviewed 1051 women seeking induced abortion in four randomly selected private clinics in Benin City between January and September 2002. The blood samples of those who accepted HIV testing were collected and screened at the University of Benin Teaching Hospital. The women were aged between 16 and 46 years (mean 31.1+/-6.7 years). One hundred and thirty seven women (13%) accepted HIV testing. Of the 1051 women, 1001 (95.2%) had multiple sexual partners and 722 (68.8%) regularly practiced unprotected sex. All were aware of HIV/AIDS. The older women were more likely to accept voluntary HIV testing than the younger ones. Acceptance rate for voluntary HIV testing was low in both the employed and unemployed and much lower among full time housewives (p = 0.01). We therefore recommend that HIV campaign programmes should include strategies aimed at arousing public interest in voluntary HIV testing.
Download full-text PDF |
Source |
---|
AIDS Patient Care STDS
January 2025
Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, California, USA.
Community health workers (CHWs) play a significant role in supporting health services delivery in communities with few trained health care providers. There has been limited research on ways to optimize the role of CHWs in HIV prevention service delivery. This study explored CHWs' experiences with offering HIV prevention services [HIV testing and HIV pre- and post-exposure prophylaxis (PrEP and PEP)] during three pilot studies in rural communities in Kenya and Uganda, which aimed to increase biomedical HIV prevention coverage via a structured patient-centered HIV prevention delivery model.
View Article and Find Full Text PDFFront Immunol
January 2025
Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Antiretroviral therapy is the standard treatment for HIV, but it requires daily use and can cause side effects. Despite being available for decades, there are still 1.5 million new infections and 700,000 deaths each year, highlighting the need for better therapies.
View Article and Find Full Text PDFInt J Public Health
January 2025
Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States.
Objectives: This study analyzes survey data across 21 countries to explore correlations between delays in blood testing and the prevalence of seven health conditions: thalassaemias, sickle cell disorders, malaria, HIV, high fasting plasma glucose, impaired kidney function, and high LDL cholesterol.
Methods: We analyzed Pandemic Recovery Survey data via multivariable logistic regression to compare blood test delays between individuals with and without medical conditions, while adjusting for sociodemographic factors. We also examined the disease burden using disability-adjusted life years (DALYs) and summary exposure values (SEV) rates.
AIDS Res Treat
January 2025
Department of Biomedical Sciences, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Atherogenic index of plasma (AIP) and high-sensitivity C-reactive protein (hsCRP) levels which are strong predictors of the risk of cardiovascular disease (CVD) seen elevated in the serum of people living with HIV (PLWH) on HAART and in those with low cluster of differentiation-4 (CD4) cell counts. Thus, this study aimed to evaluate AIP and hsCRP levels among PLWH on dolutegravir (DTG) and ritonavir-boosted atazanavir-based (ATV/r) antiretroviral therapy (ART) and their correlations to CD4 cell counts. The study design was an institutional-based comparative cross-sectional study conducted from November 4, 2021, to January 4, 2022.
View Article and Find Full Text PDFDrug Deliv Transl Res
January 2025
The Kirby Institute, UNSW Sydney, Sydney, 2052, Australia.
Using the knowledge from decades of research into RNA-based therapies, the COVID-19 pandemic response saw the rapid design, testing and production of the first ever mRNA vaccines approved for human use in the clinic. This breakthrough has been a significant milestone for RNA therapeutics and vaccines, driving an exponential growth of research into the field. The development of novel RNA therapeutics targeting high-threat pathogens, that pose a substantial risk to global health, could transform the future of health delivery.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!